Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 30, 2015 9:33 PM ET


Company Overview of Rhythm Pharmaceuticals, Inc.

Company Overview

Rhythm Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases; and obesity, including obesity caused by genetic deficiencies in the MC4 pathway. Its portfolio includes relamorelin (RM-131), a ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes and other GI functional disorders; and RM-493, a melanocortin-4 (MC4) receptor agonist for the treatment of obesity and obesity caused by genetic deficiencies in the MC4 pathway. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts.

855 Boylston Street

11th Floor

Boston, MA 02116

United States

Founded in 2008





Key Executives for Rhythm Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 61
Founder and President
Age: 56
Founder and Chief Development Officer
Age: 65
Chief Scientific Officer
Age: 60
Compensation as of Fiscal Year 2015.

Rhythm Pharmaceuticals, Inc. Key Developments

Rhythm Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:30 AM

Rhythm Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Rhythm Pharmaceuticals Inc. Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant

Rhythm Pharmaceuticals Inc. announced the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway. This RM-493 clinical trial is a new approach that targets the root cause of obesity in the MC4 heterozygote population. MC4R deficiency due to mutations in the MC4R gene has been identified as the most common monogenic cause of obesity. Up to 6% of people with a BMI >35 have MC4R deficiency, and this group has a higher predisposition than the general population for severe obesity and its complications, such as diabetes. MC4R deficiency also correlates with early-onset obesity, which lengthens exposure to the risk of obesity-associated diseases. Furthermore, MC4R deficiency may also undermine the beneficial effects of diet and exercise for weight loss, limiting treatment options for these individuals. This first MC4R deficiency trial is a Phase 1B study designed to evaluate the effect of RM-493 on weight loss and safety in obese patients with a loss-of-function variant of the MC4R gene. Patients will be treated for up to four weeks with RM-493. This study expands on Rhythm's ongoing Phase 2 clinical program for RM-493 for the treatment of obesity. RM-493 has demonstrated impressive efficacy on weight loss in both preclinical studies and early clinical trials in subjects with normal, fully functioning MC4R genes. This new clinical study a personalized medicine approach to the treatment of obesity in people with a poorly functioning MC4R gene and has the potential to restore function in this pathway and improve weight regulation. The company is excited about the potential to address this significant unmet need in metabolic disease. RM-493 is a small-peptide melanocortin 4 receptor (MC4R) agonist that is in clinical development for the treatment of obesity and diabetes. The MC4 receptor mediates a key pathway in humans that regulates energy homeostasis and food intake. The MC4R pathway is well validated in humans; loss-of-function mutations of MC4R are associated with obesity and have a reported prevalence of 4%-6% in severe obesity. In the MC4R heterozygote population, RM-493 may restore MC4R function by increasing activity in the one healthy copy of MC4R.

Similar Private Companies By Industry

Company Name Region
FunGuys LLC United States
Zeneca Holdings Inc. United States
Forgiven Bottling Group, Inc. United States
Lasko United States
Coventry Diagnostics LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Rhythm Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at